---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-149424"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:56:45.570870+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Eliem Therapeutics announces 2023 annual meeting voting results

## Summary
- Simon Tate elected as Class II director with 21,144,596 votes for, 555,897 withheld, 891,450 broker non-votes.
- Ratification of PricewaterhouseCoopers as auditor: 22,574,271 for, 3,897 against, 13,775 abstentions.
- Annual meeting held virtually on May 18, 2023; two proposals voted on.

## SEC filing metadata
- accession: 0001193125-23-149424
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312523149424/0001193125-23-149424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312523149424/d501370d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-149424
- JSON: https://secwatch.observer/filing/0001193125-23-149424.json
- Plain text: https://secwatch.observer/filing/0001193125-23-149424.txt

## Key facts
- Shareholder Votes
  Climb Bio, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-18 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: Stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312523149424/0001193125-23-149424-index.htm
- Shareholder Votes
  Climb Bio, Inc. shareholders approved Election of Class II director to serve until 2026 Annual Meeting at the 2023-05-18 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: Stockholders elected the nominee for Class II director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312523149424/0001193125-23-149424-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.